<DOC>
	<DOCNO>NCT00993122</DOCNO>
	<brief_summary>The result antiviral therapy patient recurrent hepatitis C liver transplantation lower standard . Ribavirin immune-modulating effect seem crucial optimize viral treatment . The aim multicenter control study examine effect Ribavirin pre-treatment precede combination therapy peginterferon plus ribavirin sustain virological response .</brief_summary>
	<brief_title>Ribavirin Pre-treatment Followed Combined Standard Therapy Hepatitis C Virus ( HCV ) Recipients</brief_title>
	<detailed_description>Ribavirin Pre-Treatment Study Protocol 1 . Introduction : - Recurrence hepatitis C infection liver transplant : Recurrence hepatitis C liver transplant almost universal . After liver transplantation , progression chronic hepatitis C aggressive high percentage recipient develop cirrhosis rapid liver decompensation ( 1 ) . Recent study show long-term-survival-rate significantly low compare non-HCV infected recipient ( 2 ) . Other study found antiviral treatment improves survival patient . Thus , treatment hepatitis C patient LT priority transplant unit . To date , rate sustain virologic response ( SVR ) patient recurrent hepatitis C liver transplantation 20 % standard IFN increase 30 % pegylated IFN Ribavirin ( 3 ) . Lack tolerability low compliance antiviral therapy may represent important limit factor order improve SVR . Severe myelosuppression frequent patient , due additional effect immunosuppressive therapy , additional reason reduce antiviral drug dosage ( 3 ) . - Ribavirin : Recent study evaluate effect ribavirin prim standard combine antiviral therapy immuno-competent patient chronic hepatitis C ( 4-7 ) . The conclusion study may suggest ribavirin pre-treatment may way improve SVR . 2 . Aim study : The study randomize un-blind multicenter project compare efficacy antiviral treatment RBV prim vs standard antiviral treatment patient recurrent hepatitis C liver transplantation . Ribavirin pre-treatment may : - Ameliorate therapy-compliance - Avoid concomitant drugs-related hematological side effect - Modify intra-hepatic cytokine pattern toward good antiviral action - Improve SVR . This control trial sponsor drug company . 3 . Patients : The protocol study need approved local ethic committee . Patients enrol study inform purpose protocol treatment need sign write informed consent . 4 . Statistical analysis , sample size randomization : Sample size calculation perform use EVR primary outcome measure . We assume 48 week intend treatment pegylated interferon ribavirin transplant patient recurrent hepatitis C induce EVR 60 % patient ( 10 ) . In pilot study ribavirin prim follow 48 week pegylated interferon ribavirin obtain EVR 92 % patient . To show improvement EVR 60 92 % , assume alpha level 0.05 , 90 % power ( beta =0.20 ) fifty patient per group need . Patients randomized inclusion study , use opaque envelope technique assign treatment predetermine sequence Coordinator Center . Randomization stratify genotype 1 non1 decrease likelihood uneven distribution underlie disease severity would bias result . Randomization occur block four . 5 . Definitions : The following definition go use ; study : - Rapid Virological Response : complete viral clearance week 4 - Early Virologic Response : viral reduction &gt; 2 log 12 week combine therapy . - Complete Early Virological Response : complete viral clearance 12 week combine therapy . - End treatment Virologic Response : complete viral clearance end treatment period - Sustained Virologic Response : complete viral clearance 24 week end treatment - Non Responder : Absence virological response 12 week - Relapse : recurrence viral replication complete clearance treatment time conclusion . 6 . Protocol study : Basal Evaluation : - Liver biopsy within last 6 month - Complete biochemical assessment ( liver function test , renal function , blood test , level immunosuppressive therapy ) - HCV-RNA quantitative determination Randomization : Patient randomize treatment A Treatment B ) : - Treatment A : Pre-treatment : Ribavirin start 600 mg/day ( 400mg/ day &lt; 60 kg ) increase 10,4 mg/kg within week 2 , therapy continue 8 complete week . Biochemical assessment repeat week 2 , 4 , 8 . Samples store time . HCV-RNA quantitative determination repeat week 8 . Drug reduction allow hemoglobin level 10 g/dL though EPO administration whenever consider necessary . Combined antiviral therapy : For 48 week patient treat Ribavirin ( dosage ) IFN alfa2b ( 1,5 mcg/kg/week ) . Patients follow monthly frequently require . Biochemical virological assessment record week 4 , 12 , 24 , 48 . Surveillance perform collateral effect dose adjustment growth factor need . Ribavirin reduction require hemoglobin level 10 g/dL though EPO use . IFN weekly administration reduce neutrophile count &lt; 750 spite G-CSF administration . IFN interruption require neutrophile &lt; 500 platelet &lt; 35000 . - Treatment B : For 48 week patient treat Ribavirin ( 10 mg/kg ) pegylated IFN alfa2b weekly . Ribavirin start 600 mg/day increase 10 mg/kg within week 2 . Pegylated IFN alfa2b administer weekly dose 1,5/kg/week . Patients follow twice monthly first month least monthly thereafter ( frequently whenever require ) . Biochemical virological assessment record week 4 , 12 , 24 , 48 . Surveillance perform collateral effect dose adjustment growth factor need . Ribavirin reduction require hemoglobin level 10 g/dL though EPO use . IFN weekly administration reduce neutrophile count &lt; 750 spite G-CSF administration . IFN interruption require neutrophile &lt; 500 platelet &lt; 35000 . End-points study : - Rapid Virological Response ( week 4 ) - Early Virological Response ( week 12 ) - Complete Early Virological Response ( week 12 ) - End treatment Virological Response ( week 48 ) - End treatment Biochemical Response ( week 48 ) - Sustained Virological Response ( Six month end therapy ) Collateral effect , dose adjustment use growth factor record .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Liver transplantation &gt; 6 month 2 . Positive HCVRNA viremia 3 . Elevated transaminase level ( great 1,2 normal value ) least two consecutive determination last month 4 . Histology pattern show hepatitis C recurrence 1 . Multiple organ transplantation 2 . Histology show evidence hepatic allograft rejection &gt; 3/9 RAI score 3 . Concomitant active biliary disease 4 . Concomitant HBV infection 5 . Normal transaminase level 6 . Less 1500 neutrophile one blood test 7 . Less 50000 platelet one blood test 8 . Hemoglobin &lt; 9 g/ dL 9 . Creatinine clearance &lt; 35 ml/min 10 . Positive antibody &gt; 1:80 11 . Autoimmune thyroid pathology 12 . Severe psychiatric disease 13 . Diagnosis ischemic cardiopathy last 12 month 14 . Active alcohol abuse 15 . Low compliance medical treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>pre treatment</keyword>
	<keyword>therapy compliance</keyword>
	<keyword>SVR</keyword>
	<keyword>sustained virological response</keyword>
	<keyword>TH1 TH2 ratio</keyword>
</DOC>